- Trial Phase
- Phase 1/2
- Time to Market
- Unknown — at least 3-5 years if Phase 1/2 data is positive, followed by Phase 3 trials and FDA review. The Fast Track designation could accelerate the timeline.
- Why 6/10
- The next hard, dated catalyst is the Phase 1/2 first-cohort topline data readout expected in Q4 2026 (~3 months away). ATR-04 is one of Azitra's two clinical programs (alongside the paused ATR-12), and the company's entire ~$2.3M market cap is essentially a call option on this readout and the cash runway. The score is 6 (not higher) because this is an early Phase 1/2 safety/efficacy readout — not a pivotal Phase 3 or PDUFA — and the company has other pipeline programs (ATR-COSF) and a very limited cash runway that creates a separate overhang.
Watch for ATR-04 Phase 1/2 first-cohort topline data expected Q4 2026 — positive safety/efficacy signals could drive a sharp rally given the tiny market cap, but the ~6-month cash runway means a dilutive financing is likely before year-end regardless of results. The stock is a high-risk binary play on a single early-stage asset.
Price Chart
Executive Summary
ATR-04 (ATR04-484) is Azitra's topical live biotherapeutic product candidate for treating moderate-to-severe skin rash caused by EGFR inhibitor cancer therapy. It uses an engineered auxotrophic strain of Staphylococcus epidermidis (SE484) designed to reduce inflammation (IL-36g) and inhibit S. aureus. The FDA granted Fast Track designation in March 2026. A Phase 1/2 randomized, double-blind, vehicle-controlled trial began dosing in August 2025, with topline data from the first cohort expected in Q4 2026. Azitra (NYSE American: AZTR) is a micro-cap clinical-stage biopharma with ~$6.7M cash, a ~$2.3M market cap, and roughly 6 months of runway — the ATR-12 Netherton Syndrome study was paused to conserve cash. Analyst consensus is bullish (6 Buy/Strong Buy, 1 Hold) with a mean price target of $0.775 (~335% upside), but the cash burn and dilution risk are significant.
How It Works
ATR-04 is a topical cream containing a live, engineered strain of a common skin bacterium (Staphylococcus epidermidis). The strain is 'auxotrophic' — modified to be dependent on an external nutrient so it cannot survive independently — making it safer. It works by reducing the inflammatory protein IL-36g and inhibiting Staphylococcus aureus, a bacteria that can worsen skin rashes. It is designed to treat the painful, itchy skin rash that many cancer patients develop from EGFR inhibitor drugs.
Trial Status
A Phase 1/2 multicenter, randomized, double-blind, vehicle-controlled trial (Yale Medicine) began dosing the first patient in August 2025. The primary goal is safety and tolerability; secondary goals include efficacy signals. The trial is actively enrolling. Topline data from the first cohort is expected in Q4 2026.
The Two-Sided Case
Upcoming Catalysts
- Topline data from first cohort of Phase 1/2 trial expected Q4 2026
- Potential dilutive financing given ~6-month cash runway
- ATR-COSF cosmetic program human study planned Q3 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Azitra, Inc. PRESS-RELEASE AZTR ·Originating report